Core Viewpoint - Black Diamond Therapeutics, Inc. reported its financial results for Q4 and the full year of 2024, highlighting advancements in its clinical programs, particularly BDTX-1535 for treating patients with EGFRm NSCLC and glioblastoma [1][2]. Financial Highlights - Cash, cash equivalents, and investments totaled approximately 131.4 million in 2023, which is expected to fund operations into Q4 2026 [5][7]. - Net loss for Q4 2024 was 19.4 million in Q4 2023. The total net loss for the year was 82.4 million in 2023 [6][13]. - Research and development expenses decreased to 15.3 million in Q4 2023, and for the full year, R&D expenses were 59.4 million in 2023 [6][13]. Clinical Developments - The company is advancing BDTX-1535 in a Phase 2 trial for newly diagnosed patients with non-classical EGFRm NSCLC, with initial data expected in Q2 2025 [5][6]. - An expansion of the investigator-sponsored "window of opportunity" trial into newly diagnosed glioblastoma patients with EGFR aberrations is anticipated in Q1 2025 [5][6]. - The company plans to seek FDA feedback on a potential pivotal registrational path for BDTX-1535 in the second half of 2025 [6]. Upcoming Milestones - Initial Phase 2 clinical data for BDTX-1535 in non-classical EGFRm NSCLC patients is expected in Q2 2025 [5][6]. - Updated Phase 2 clinical data for recurrent EGFRm NSCLC patients is anticipated in the second half of 2025 [6]. - The trial for glioblastoma patients is set to transition from a Phase 0/1 to a Phase 0/2 trial in Q1 2025 [6]. Company Overview - Black Diamond Therapeutics is focused on developing MasterKey therapies targeting oncogenic mutations in cancer patients, with a specific emphasis on addressing unmet medical needs in NSCLC and glioblastoma [1][8].
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update